Servier, an independent international pharmaceutical group governed by a foundation, announces the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share. The acquisition strengthens Servier’s leadership in low-grade glioma and expands the Group’s position in oncology with the addition of a marketed product and pipeline focused on rare cancers.
Read the full article: Servier Completes the Acquisition of Day One Biopharmaceuticals //
Source: https://www.prnewswire.com/news-releases/servier-completes-the-acquisition-of-day-one-biopharmaceuticals-302751635.html